MX2021002993A - Métodos para el tratamiento de la hipertrofia del músculo masetero. - Google Patents

Métodos para el tratamiento de la hipertrofia del músculo masetero.

Info

Publication number
MX2021002993A
MX2021002993A MX2021002993A MX2021002993A MX2021002993A MX 2021002993 A MX2021002993 A MX 2021002993A MX 2021002993 A MX2021002993 A MX 2021002993A MX 2021002993 A MX2021002993 A MX 2021002993A MX 2021002993 A MX2021002993 A MX 2021002993A
Authority
MX
Mexico
Prior art keywords
methods
masseter muscle
kits
vehicle
reducing
Prior art date
Application number
MX2021002993A
Other languages
English (en)
Inventor
Christine Somogyi
Elisabeth Lee
Beta Bowen
John D Rogers
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2021002993A publication Critical patent/MX2021002993A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Traffic Control Systems (AREA)

Abstract

Se describen métodos y kits para tratar o aliviar la hipertrofia del músculo masetero mediante la administración local de un derivado clostridial, tal como una toxina botulínica, al músculo masetero. También se describen métodos y kits para reducir la anchura de la cara inferior y para reducir la prominencia del músculo masetero de un ser humano.
MX2021002993A 2018-09-13 2019-09-12 Métodos para el tratamiento de la hipertrofia del músculo masetero. MX2021002993A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731064P 2018-09-13 2018-09-13
PCT/US2019/050910 WO2020056204A1 (en) 2018-09-13 2019-09-12 Methods for treatment of masseter muscle hypertrophy

Publications (1)

Publication Number Publication Date
MX2021002993A true MX2021002993A (es) 2021-08-11

Family

ID=68069888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002993A MX2021002993A (es) 2018-09-13 2019-09-12 Métodos para el tratamiento de la hipertrofia del músculo masetero.

Country Status (11)

Country Link
US (3) US20200085923A1 (es)
EP (1) EP3849585A1 (es)
JP (1) JP2022500417A (es)
KR (1) KR20210057106A (es)
CN (1) CN112955166A (es)
AU (1) AU2019337656A1 (es)
BR (1) BR112021004776A2 (es)
CA (1) CA3112227A1 (es)
MX (1) MX2021002993A (es)
TW (1) TWI835858B (es)
WO (1) WO2020056204A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
CA2501856A1 (en) * 2002-10-15 2004-04-29 Allergan, Inc. Botulinum toxin dental therapies and procedures
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
WO2006073410A1 (en) * 2005-01-03 2006-07-13 Botulinum Toxin Research Associates, Inc. Compositions, methods and devices for preparing less painful botulinum toxin formulations
WO2009139739A1 (en) * 2006-02-14 2009-11-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
RU2535115C1 (ru) * 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
WO2017075468A1 (en) * 2015-10-29 2017-05-04 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Also Published As

Publication number Publication date
JP2022500417A (ja) 2022-01-04
AU2019337656A1 (en) 2021-05-06
WO2020056204A1 (en) 2020-03-19
BR112021004776A2 (pt) 2021-11-09
KR20210057106A (ko) 2021-05-20
CA3112227A1 (en) 2020-03-19
CN112955166A (zh) 2021-06-11
US20200085923A1 (en) 2020-03-19
US20230080740A1 (en) 2023-03-16
TWI835858B (zh) 2024-03-21
TW202023606A (zh) 2020-07-01
EP3849585A1 (en) 2021-07-21
US20230083250A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
EP3628559A3 (en) Fault alarm method and device for automatic driving system
WO2019140277A8 (en) Monitoring system for autonomous vehicle operation
MX2020013267A (es) Estimacion del desgaste de llanta utilizando un metodo y sistema de aprendizaje por maquina hibrido.
WO2020102396A3 (en) Redundancy system and method
MX2019010307A (es) Metodo de asistencia a la conduccion y dispositivo de asistencia a la conduccion.
MX2020013065A (es) Sistema de control remoto del vehiculo, modulo de comunicacion, vehiculo, servidor, metodo de control remoto del vehiculo, programa de control remoto del vehiculo y medio de almacenamiento.
EP4035962A3 (en) Automatic driving control device and automatic driving control method
WO2011130585A3 (en) System and method for driver training in a controlled driving environment
ATE534867T1 (de) Sicherheitsvorrichtung und verfahren zur überwachung eines überwachungsbereichs
TW200623629A (en) Anti-cross conduction driver control circuit and method
WO2007074105A3 (de) Verfahren zur anlagenüberwachung mit einem feldbus der prozessautomatisierungstechnik
MX2016006478A (es) Un metodo y un sistema para aumentar la atencion del conductor.
MX2016009391A (es) Sistemas y metodos de control de estabilidad de la bicicleta.
MX2018003193A (es) Sistema y método para manejo seguro en puertas enrollables.
WO2019076346A9 (zh) 下行控制信息的传输、盲检测次数的获取方法和装置
Stevenson et al. On the road to prevention: road injury and health promotion
MX355176B (es) Sistema y método de detección y ejecución de alineación de agujas.
SG10201804179PA (en) Equipment condition-based corrosion life monitoring system and method
DE502004007061D1 (de) Verfahren und vorrichtung zum steuern eines sicherheitskritischen prozesses
MX2010002176A (es) Alertador cognitivo.
WO2013164224A3 (de) Verfahren und vorrichtung zur überwachung von funktionen eines rechnersystems, vorzugsweise eines motorsteuersystems eines kraftfahrzeuges
MX2021002993A (es) Métodos para el tratamiento de la hipertrofia del músculo masetero.
MY196790A (en) Method for controlling direction indicator and device for controlling direction indicator
TW200739509A (en) Method and system for lowering the drive potential of an electrochromic device
Xiaoyong et al. Research on Turnout Switching Intelligent Diagnosis System Based on PHM